Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Clinical trials for JOURNAVX were conducted at four CenExel Centers of Excellence in Salt Lake City, UT; Tampa, FL; Anaheim, CA; and Atlanta, GA. These sites provided critical data that ...